(Health Korea News / Changyong Lee) Daewon Pharmaceutical was found to have achieved good performance in the third quarter of this year.
According to information announced by the company on the 14th, operating profit in the third quarter of this year was KRW 11.3 billion, a 68.79% increase compared to the same period last year (KRW 6.7 billion).
Sales and net profit also increased by 21.59% and 5.82%, respectively, compared to the same period last year, to KRW 156.8 billion and KRW 5.6 billion.
Cumulative sales for the first to third quarters amounted to KRW 453 billion, an increase of 17.35% compared to the same period last year (KRW 386 billion). However, cumulative operating profit and accumulated net profit decreased by 3.02 and 45.93% compared to the same period last year, respectively, to KRW 25 billion and KRW 12.3 billion.
(Daewon Pharmaceutical’s consolidated operating performance for the third quarter of 2024)
|
division(unit: million won%) |
Current performance |
previous year performance |
Rate of change compared to the previous quarter |
Performance for the same period last year |
Rate of change compared to the same period last year |
|
|
(24year 3branch) |
(24year 2branch) |
(23year 3branch) |
||||
|
take |
Current performance |
156,831 |
137,959 |
13.68% |
128,979 |
21.59% |
|
Cumulative performance |
453,091 |
– |
– |
386,099 |
17.35% |
|
|
operating profit |
Current performance |
11,380 |
-1,354 |
Turn into surplus |
6,742 |
68.79% |
|
Cumulative performance |
25,004 |
– |
– |
25,782 |
-3.02 |
|
|
net profit |
Performance of the year |
5,639 |
-2,269 |
Turn into surplus |
5,329 |
5.82 |
|
Cumulative performance |
12,359 |
– |
– |
22,859 |
-45.93 |
|
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
